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Abstract
Background: Myomectomy is a surgical technique used for removal of uterine fibroids and historically hysterectomy
has represented the mainstay of treatment. The options of conservative surgical approaches mainly aim at retention of fertility but have to be balanced against potential risks such as haemorrhage; blood loss at myomectomy
still remains troublesome with use of various pharmacologic agents yielding inconclusive results. This trial aimed to
explore the benefit of combining ornipressin and tranexamic acid during open myomectomy.
Study design: A randomized double blind placebo controlled trial.
Methods: Women who satisfied eligibility criteria were enrolled into the study and randomized into one of two
groups. The experimental group received 1 g of tranexamic acid diluted to 50 ml of saline administered at 100 ml
per hour at cutting time (knife to skin). The control group received placebo diluted to 50 ml of saline administered at
100 ml per hour at cutting time. Both groups had five international units ornipressin diluted in 60 ml of saline administered during surgery. The primary outcome (blood loss) was assessed by determining the weight difference of dry
and soaked swabs using a digital weighing scale by converting this to volume (ml). Operating time was noted from
the time of uterine incision to the time of uterine closure. The need for transfusion was determined by anaesthetists’
assessment of acceptable blood loss and clinical assessment of vital signs. Post-operative stay was calculated from the
time of extubation to 8 am on the day of discharge.
Results: A total of thirty-four patients were randomized to two groups; 17 received ornipressin only and 17 received
tranexamic acid and ornipressin. There was no difference in blood loss between the groups with a median blood loss
in the ornipressin (n = 17) and ornipressin plus tranexamic acid arms of 398 ml (IQR: 251–630) ml and 251 ml (IQR:
158–501) ml respectively P = 0.361.
Conclusions: Ornipressin administered along with tranexamic acid is not beneficial for blood loss reduction at open
myomectomy. In settings such as ours where myomata are prevalent and severe anaemia rampant, blood donation
and judicious use of scarce blood resources is key. Efforts to optimize preoperative haemoglobin levels and blood
auto-donation seem the most promising options in pre-operative preparation prior to myomectomy.
Clinical Trials Registration Number: PACTR201203000369163
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Background
Uterine myomata are the most common benign solid
tumours of the female genital tract and are diagnosed
in about 25–30 % of women [1]. The overall prevalence
of fibroids in Black African population is estimated at
50–75 %, forming the primary diagnosis for 61 % of black
and 29 % of white women [2]. Several options are available for the management of symptomatic fibroids. These
can broadly be grouped into expectant, medical and surgical methods. Surgical methods include uterine fibroid
embolization, laparoscopic myomectomy, hysteroscopic
resection, hysterectomy or open myomectomy. Myomectomy carries a significant risk of haemorrhage with a
transfusion rate of 21 % [3]. Several interventions to
reduce blood loss have been explored including vasopressin analogues, antifibrinolytic agents, and gonadotropin
releasing hormone analogues, oxytocin, misoprostol and
mechanical tourniquets [4]. These studies have drawn
conclusions from single agents versus placebo but none
has utilized adjunct techniques against methods considered standard protocol. At the Aga Khan University
Hospital the use of ornipressin is considered standard
practice by most gynaecologists during open myomectomy and has occasionally been utilized with other additional drugs like tranexamic acid in an attempt to reduce
intra operative haemorrhage. There are no randomized
trials comparing adjunctive use of tranexamic acid along
with ornipressin during open myomectomy and hence
the need to establish its utility when used along with
ornipressin.
Methods
Study design

This randomized double blind controlled trial compared
blood loss between two groups of participants, one receiving
ornipressin only and the other ornipressin and tranexamic
acid. Patients were recruited from the gynaecology clinics at
the Aga Khan University Hospital. Patients with documented
uterine fibroids on ultrasound scan were recruited following
discussion and gave written consent to participate.
The sampling frame included all women attending
gynaecology clinic at the Aga Khan University Hospital. Patients with symptomatic uterine fibroids-heavy
menses, pressure symptoms, and painful menses were
recruited for the study. Study subjects were eligible to be
enrolled into the study if they had documented symptomatic uterine fibroids by ultrasound imaging, written
informed consent, no prior treatment using gonadotropin releasing hormone analogues, no family history of
bleeding disorder, no current use of anticoagulants, and
no prior history of deep venous thrombosis. They were
excluded if they had poorly controlled hypertension
or diabetes and previous uterine fibroid embolization.
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Sample size calculation was set at 90 % power to detect a
150 ml difference in blood loss, with a significant level of
5 % and a one sided alpha of 0.05 and beta (β)-set at 0.1.
The sample size was calculated using the formula
below.

N = 2� 2 (zα + Z1/2β)2 /r2
Substituting with figures:


N = 2 × 135 × 135(1.96 + 1.282)2 1502
= 17 patients in each group.
Patients with documented evidence of uterine fibroids
on ultrasound who had decided on open myomectomy
were enrolled at the gynaecology outpatient clinic. At
this point the surgical procedure informed consent was
signed. Block randomization was achieved by a computer generated sequence operated by the pharmacist.
The computer generated list of interventions consisted
of four blocks containing a plain normal saline in 50 ml
syringe and one gram of tranexamic acid diluted to
50 ml of normal saline. Random allocation to each block
was made and patients allocated as per the flow of the
block sequence as indicated so as to achieve allocation
concealment.
1. TTPP

4.

PTPT

7.

PTTP

2. TPTP

5.

PPTT

8.

TTPP

3. PTTP

6.

PTPT

9.

TPTP

where T is test (Tranexamic acid) and P is Placebo (Normal Saline).
This ensured even distribution in both arms of the
study [5].
The study assistant submitted the patient’s identification to the pharmacist which was entered against the
intervention allocated thus keeping the randomization
code unknown to the study assistant. Aseptically freshly
prepared solution (50 ml syringe) of 1 g tranexamic acid
in 50 ml or 50 ml normal saline (placebo) was issued to
the study assistant packed in an opaque envelope and
delivered to the operating room. Tranexamic acid prepared in the pharmacy is a clear solution that was diluted
to 50 ml in a normal saline solution and therefore indistinguishable to the 50 ml normal saline placebo, thus
assuring blinding of the surgeon, anaesthetist and data
collector. The study assistant delivered the dispensed
solution to theatre. The 50 ml solution loaded onto the
infusion pump was started at cutting time (knife to
skin) running at a rate of 100 ml per hour. All study participants enrolled received ornipressin (5 international
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units diluted to 60 ml) infiltrated around the myomata.
Soaked swabs were weighed and blood loss estimated by
subtracting the soaked weight from the dry weight and
multiplied by 1.050 to convert to volume in ml [6]. The
myomata location was documented post operatively by
the surgeon.
Duration of surgery was calculated in minutes noted
from the time of incision on the uterus to placement of
the last uterine stitch, by the theatre circulating nurse.
Post-operative stay was calculated from the time of extubation to 8 am on the day of discharge in hours after
satisfying discharge criteria (Appendix). The volume
of the myoma was determined using the Archimedes
principle by immersion of all the fibroids in a measuring cylinder with water calibrated in ml. The need for
transfusion was assessed by the anaesthetist if there
was significant haemorrhage defined by the vital signs
BP 90/60 mmHg or lower, heart rate >110 b/min and
or a calculated threshold of blood loss necessitating
transfusion obtained by: Hb threshold of 8 g/dl, therefore allowable blood loss was considered equal to total
Blood volume (Pre-operative Hb − Hb threshold/Pre
op Hb). Blood loss beyond this threshold necessitated
blood transfusion. Serious adverse outcomes of the
study included death, massive transfusion >5 units of
blood, development of deep venous thrombosis pulmonary edema and pulmonary embolism. The study was
approved by the Aga Khan University Research Ethics
Committee.

Fig. 1 Flow of study participants
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Results
Participant flow for the study is shown in Fig. 1. Data were
available for 17 participants in each group. Clinical and
operative findings are presented in Table 1. Operating time
and estimated blood loss are shown in Table 2. There were
no major postoperative complications or study medication related adverse events in either group. Data analysis
was performed using STATA version 12 special edition
(STATA/SE). Categorical variables were summarized as
frequencies (n) and the corresponding percentages (%)
while the continuous variables that were normally distributed were summarized as mean and the corresponding
standard deviation (std). Continuous variables that were
skewed were transformed using the logarithm to base 10.
The variables that were transformed were blood loss, operation time, and myoma volume. The test for differences
between the categorical variables and the treatment group
was conducted using the Pearson’s Chi Square test and
because of the small cell counts for all the variables Fisher’s exact was utilized. The relationship between the continuous variables was assessed using Pearson’s correlation
coefficient. The test for differences in the continuous variables between the treatment groups was done using the
two-sample t test if the normality assumption was holding.
However, if the normality assumption was violated, then a
two sample Wilcoxon rank sum test was used. The test for
differences in the continuous variables between the treatment groups was done using the two-sample t test. Assessment for the validity of a t test was also done.
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Table 1 Demographic and baseline clinical characteristics in both groups
Variables

Group

Continuous variables

P

Ornipressin only (n = 17)

Tranexamic acid and ornipressin (n = 17)

Mean (std)

Mean (std)

Age (years)

35.0 (3.9)

36.0 (4.3)

0.536

Pre operation HB

12.8 (1.3)

12.6 (1.9)

0.760

BMI (kg m−2)

29.9 (3.7)

29.6 (2.8)

0.775

Categorical variables

n (%)

n (%)

P

0.261

Indication for surgery
12 (71 %)

14 (82 %)

Pressure symptoms

Heavy menses

2 (12 %)

3 (18 %)

Subfertility

3 (18 %)

0 (0)

Uterine incision
Anterior vertical

9 (53 %)

8 (47 %)

Anterior transverse

2 (12 %)

2 (12 %)

Bonney’s Hood

1 (6 %)

0 (0 %)

Posterior transverse

1 (6 %)

2 (12 %)

Posterior vertical

4 (24 %)

5 (29 %)

Intramural

15 (88 %)

13 (76 %)

Subserosal

2 (12 %)

4 (24 %)

1.000

Position of myoma
0.656

Table 2 Outcomes in both groups
Continuous variables

Blood loss

a

Intra operative time (min) t − 0.23;
df = 32; P = 1.000

Post-operative stay (h) (t − 1.69,
P = 0.100)

Post operation HB

Group

P

Ornipressin only (n = 17)

Tranexamic acid and ornipressin (n = 17)

Mean (std)

Mean (std)

398 ml (251–630) ml

251 ml (158–501) ml

0.361

50.1

50.1

1.000

67.88 (22.98)

55.03 (21.22)

0.100

10.2 (2.1)

10.3 (1.9)

0.939
1.000

Surgicel use
Yes

4 (24) %

4 (24) %

No

13 (76) %

13 (76) %

a

The two sample Wilcoxon rank sum test for differences in quantity of blood loss between the ornipressin and the ornipressin plus tranexamic arms showed no
evidence of statistically significant difference. Data were log transformed

There was no variable that appeared to confound the
true effect of the treatment. There were no missing data
for all the variables.
A strong statistically significant association between
myoma volume and blood loss was identified (Fig. 2).
Stratified by the treatment arm, the same trend was seen
with correlation coefficient equal to 0.890 in the ornipressin and tranexamic acid group and 0.850 in the ornipressin group (P < 0.0001).

Discussion
This study found that there is no additional benefit in
adjunct tranexamic acid use to ornipressin during open
myomectomy. This is the first study to our knowledge to
investigate adjunctive use of tranexamic acid along with
intramyometrial ornipressin during open myomectomy
to assess for intraoperative blood loss. Open myomectomy remains a surgical option for women of low parity with large myomata desiring fertility. Haemorrhage
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Fig. 2 Myoma volume and blood loss

is a possibility and use of various agents to reduce blood
loss is vital. There are no studies with similar objectives to compare blood loss reduction when multiple
agents are used adjunctively. Concerns of utilizing hormonal tourniquets and substances that increase uterine
tone at myomectomy include concealing active bleeders that eventually become active post operatively leading to post-operative haemorrhage, not to mention other
untoward effects like fever, chills and rigors with the use
of misoprostol [7]. The ‘triple tourniquet’ technique has
been used and showed significant results in blood loss
reduction at myomectomy [8] compared to gonadotropin
releasing hormone analogues. According to our findings
large myomata are more likely to bleed as depicted by
the correlation co efficient of 0.89 in the ornipressin plus
tranexamic acid group and 0.85 in the ornipressin group.
This indicates that the amount of blood loss is dependent on the volume of the myoma removed. It can therefore be insinuated that use of techniques that will reduce
myomata volume pre operatively are likely to reduce
blood loss at surgery. Gonadotrophin releasing hormone
analogues have been utilized pre operatively with substantial reduction in myoma volume and correction of
anaemia [8] however multiple challenges including cost,
unfavorable side effects (menopausal symptoms, loss of
bone mineral density hot flushes etc.) have limited its
use. Other concerns include fibroid recurrence after cessation of gonadotrophin releasing hormone analogue use
as well as difficult dissection planes encountered intraoperatively [8].
Uterine fibroid embolization offers a plausible alternative to open surgery for fibroids especially for patients not
keen on surgery or whose indication for hysterectomy is
due to uterine fibroids and has become a well established
modality offered in our unit. A case series in Turkey compared participants who had UFE before myomectomy
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and those who had myomectomy alone; their conclusion
was that there was significant reduction in intra operative
blood loss and a 13 % need for transfusion in the latter
group [9]. It is unclear whether this combined approach
is really clinically useful given the additional costs of two
interventions and it is not our standard practice.
One patient was excluded at recruitment who had been
re admitted due to heavy menses and pressure symptoms
after having uterine fibroid embolization 2 years before.
The use of fibroid embolization for patients keen on fertility however remains unclear, open myomectomy still
offers better pregnancy outcomes. The Mara trial concluded spontaneous miscarriage rates were higher in
patients who underwent fibroid embolization, 60 % versus 23 % in those who had open myomectomy [10]. This
study population had 8.8 % of participants whose indication for surgery was subfertility.
Additional efforts pre operatively include optimizing
haemoglobin levels using oral or parenteral haematinics,
gonadotropin agonists and encouraging auto donation
of blood to avoid risks of blood transfusion like allergic
reactions, infections, transfusion associated lung injury
and transfusion associated circulatory overload [11].
Uterine fibroids are more prevalent in the black population and possibly larger in volume; multiple large
fibroids will ultimately require judicious surgical skill
to minimize blood loss. Surgeons intending to perform
myomectomies for large myoma especially in settings
where patients are symptomatic for anaemia need to
consider optimizing pre-operative haemoglobin and prepare blood before surgery. Transfusion may be inevitable
when an initial haemoglobin level is already low and its
complications likely due to multiple transfusions hence
the importance of optimizing haemoglobin pre operatively. Human and financial resources remain scarce in
the local setting and health policy makers need to invest
in strengthening referral systems, optimizing blood
donation processes and ensuring quality training of service providers who will offer patients options for correct
management of fibroids even if it means conservative
approaches through to uterine fibroid embolization.
The findings of this study additionally shed light on
the unexplored combined use of various pharmacologic
agents at myomectomy. The study was powered to detect
the difference in blood loss at ninety percent power and
based on this, a difference in blood loss was not observed
between both groups. In future, studies of this nature
should probably attempt to obtain a sample size based
on how much blood loss would like to be avoided so as
to recruit those who bleed excessively beyond a preset
threshold. This will require a large number of participants
and possibly as a multi-center study to demonstrate the
true effect of the intervention on patients who are likely

Ngichabe et al. Ann Surg Innov Res (2015) 9:10

to bleed excessively. The study had proper randomization and blinding yielding the true effect of the intervention and both groups were similar at baseline making the
results generalizable. Most Kenyan rural institutions may
not have the advantage of having hormonal tourniquets
due to cost, thus application of similar interventions may
be hindered.
Strengths

Randomization and blinding was achieved satisfactorily.
The surgeon, principal investigator and anaesthesiologist undertaking procedure in theatre were blinded to the
intervention hence eliminating potential bias in theatre.
This ensured the true effect of intervention being captured which is key in studies of this nature. Secondly all
patients received the intervention at the same time and
same flow rate by use of an infusion pump, something
similar studies have failed to standardize.
Limitations

Surgeon’s technique at myomectomy could not be fully
standardized due to various myoma positions.
Conclusion

Adjunct tranexamic acid use to ornipressin during open
myomectomy does not have any benefit in reducing
blood loss. Large myoma volume notably found in the
black population are likely to bleed and hence there is a
need for judicious surgical skill and strategies to reduce
blood loss.
Authors’ contributions
SN-Concept, literature review and methodology execution. TO-Contributed
to study design and review of manuscript. WS Participated in study design.
Critically reviewed the manuscript for content. All authors read and approved
the final manuscript.
Author details
1
Department of Obstetrics and Gynaecology, Aga Khan University, Nairobi,
Kenya. 2 Department of Obstetrics and Gynaecology, Aga Khan University,
Nairobi, Kenya. 3 School of Medicine, University of St Andrews, St Andrews, UK.
Acknowledgements
Dr. Abraham Mukaindo, Dr. Patricia Muthaura, Dr. Sikolia Wanyonyi, Dr. Sammy
Kyalo, Dr. Alfred Murage, Dr. Johnstone Miheso, Dr. Wangira Musana, Dr. PS
Patel, Dr Evan Sequeira, Dr. Samina Mir, Dr. Edna Gisore, Dr. David Nekyon, Dr.
Jimmy Kabugi, Dr. Charles Muriuki, Dr. Ingrid Gichere, Dr. Salim Ibtisam, for
patient recruitment, consenting, pre and post -operative work up and intra
operative facilitation of the study procedures, Mr. Alfred Keter for Data entry
and analysis, Ciru Kamanda and the entire research support unit Aga Khan
University for facilitating research and ethics reviews and Nasra Gathoni, Aga
Khan University Library for literature review facilitation.
Funding
This work was funded as an MMed Dissertation project by the Aga Khan
University, Nairobi Kenya.

Page 6 of 6

Competing interests
The authors declare that they have no competing interests.

Appendix: Discharge criteria
••  Patient in good general condition.
••  Normal vital signs (Blood pressure, Heart Rate, Temperature).
••  Second day post operative haemoglobin done and
recorded in the file.
••  No clinical and laboratory pointers of infection.
••  Patient remains discharged from the study even if she
is still in the ward but sorting out other non medical
issues e.g. hospital fees, awaiting drugs.
•• 
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